Risk Management and Healthcare Policy (Mar 2022)
Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
Abstract
Yao Wang,1,2 Kaiyu Huang,1,2 Sijia Sun,1,2 Yahong Deng,1,3 Xuefeng Xie1,2 1School of Pharmacy, Anhui Medical University, Hefei, 230032, People’s Republic of China; 2Inflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Hefei, People’s Republic of China; 3Department of Pharmacy, First Affiliated Hospital of Anhui Medical University, Hefei, 230000, Anhui, People’s Republic of ChinaCorrespondence: Xuefeng Xie, School of Pharmacy, Anhui Medical University, 81 Meishan Road, Hefei, 230032, People’s Republic of China, Tel +8613721098599, Fax +86551-65161040, Email [email protected]: The rational choice of drugs for treating patients with advanced non-small-cell lung cancer (NSCLC) is significantly impacted by changes in modern drug policy, health insurance negotiation, and budget impact analyses. Here, we provide a basis for rational drug use decisions in clinical practice and promote the widespread use of pharmacoeconomic methods in clinical decision-making based on current drug policies in China and real-world data.Methods: A Markov model was developed to evaluate the health and economic outcomes in patients with advanced NSCLC treated with first-line chemotherapy with gefitinib and gefitinib plus chemotherapy. Clinical data, cost, and utility data were extracted from published literature or real-world data; sensitivity analysis was performed to assess the uncertainty in the results. The results were summarized as QALYs and the ICER.Results: The average cost and QALYs associated with gefitinib and gefitinib plus chemotherapy strategies were $62,882.83 and 1.70 and $84,509.30 and 1.93, respectively. The ICER for gefitinib plus chemotherapy versus gefitinib alone was $95,135.50. The one-way sensitivity analysis showed that the utility value of progressive disease (PD) had the greatest impact on the treatment outcome. Probabilistic sensitivity analysis showed that if China’s willingness to pay threshold was $33,300/QALY, the probability of superiority of the gefitinib plus chemotherapy regimen was 0.Conclusion: The study suggests that, from the perspective of the Chinese health system, gefitinib plus chemotherapy is not a cost-effective option for NSCLC patients with EGFR mutations. These findings may help clinicians make the best treatment decisions for patients with NSCLC.Keywords: gefitinib, Markov model, cost effectiveness, NSCLC
